Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06860958 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Mar 20, 2026 to Mar 20, 2027 Completion date: Aug 20, 2026 to Aug 20, 2027v3 Show 1 more changeShow less
    • Completion date: Aug 20, 2026 to Aug 20, 2027
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Mar 20, 2025 to Mar 1, 2025 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Mar 20, 2025 to Mar 1, 2025
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Tanta University
394 trials monitored
See 11 trials at risk
Depression
2,998 trials monitored
See 166 trials at risk
Major depressive disorder (MDD) is one of the most common psychiatric disorders with serious socioeconomic consequences on daily life and health care costs. Despite the advent of newer antidepressants that target monoamine pathways, nearly 50% of patients have no response to first-line antidepressant therapy. Thus, a combination of medications with different strategies at the beginning of treatment could provide further therapeutic benefits to MDD patients
Trial Details
NCT Number NCT06860958
Lead Sponsor Tanta University
Conditions Depressive Disorder, Major
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov